When Treatment Begins After the Bite
Placeholder: earlier treatment start improves outcomes.
- ~5 d: Median bite-to-treatment (Placeholder figure)
- ~95%: Early-stage cure rate (Placeholder figure)
- ~65%: Delayed-stage cure rate (Placeholder figure)
- 3–30 d: Erythema migrans window (Placeholder figure)
Why timing matters
Placeholder: short paragraph on dissemination risk over time.
Early Spirochete Clearance Window
Placeholder: first five days show the steepest load decline.
- ~60%: Day-5 load reduction (Placeholder figure)
- ~2 h: Peak plasma conc. (Placeholder figure)
- ~18 h: Half-life (Placeholder figure)
- 2x/day: Dosing frequency (Placeholder figure)
Early pharmacodynamics
Placeholder: short paragraph on bactericidal action.
Continued Clearance Through Mid-Course
Placeholder: sustained dosing continues reducing residual burden.
- ~90%: Day-14 load reduction (Placeholder figure)
- ~70%: Symptom resolution (Placeholder figure)
- High: Adherence importance (Placeholder figure)
- 14 d: Typical course (early) (Placeholder figure)
Mid-course dynamics
Placeholder: short paragraph on adherence and dosing.
Completing Disseminated-Stage Courses
Placeholder: disseminated cases require the full 21-day course.
- 21 d: Disseminated course (Placeholder figure)
- ~15%: Late-stage load floor (Placeholder figure)
- Elevated: Relapse risk if short (Placeholder figure)
- Possible: Neuro involvement (Placeholder figure)
Why longer courses help
Placeholder: short paragraph on disseminated-stage duration.
Cure Probability by Stage and Duration
Placeholder: final cure probability combines stage and course length.
- ~98%: Best-case cure (Placeholder figure)
- ~30%: Worst-case cure (Placeholder figure)
- Strong: Course-length effect (Placeholder figure)
- Strong: Stage effect (Placeholder figure)
Reading the gauge
Placeholder: short paragraph on interpreting the outcome gauge.
Placeholder: short callout on matching course length to disease stage.